Skip to content

Identification of New Candidate Genes for Hereditary Predisposition to Uveal Melanoma

Identification of New Candidate Genes for Hereditary Predisposition to Uveal Melanoma

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06550674
Acronym
IGCMU
Enrollment
50
Registered
2024-08-13
Start date
2024-10-29
Completion date
2028-04-01
Last updated
2026-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uveal Melanoma

Keywords

uveal melanoma, hereditary predisposition, candidate genes identification

Brief summary

Only 20% of familial uveal melanomas are explained by a hereditary predisposition, implying the presence of as yet unknown hereditary predispositions. This hypothesis is reinforced by epidemiological studies revealing an excess risk of prostate cancer, thyroid cancer and leukemia in patients who have developed uveal melanoma, even though these cancers are not part of the tumor spectrum of known hereditary predispositions to uveal melanoma (BAP1, MBD4). The identification of new candidate genes, once validated, would enable us to offer these families appropriate surveillance.

Interventions

GENETICConstitutional exome analysis

For each patient included: * A family tree is drawn up, reporting personal and family histories of cancer. The patient's anatomopathological reports, related to his or her tumor lesions, are retrieved, in order to confirm/clarify individual or family diagnoses. * A blood sample and a jugal smear are taken to enable constitutional genetic exome analysis for research purposes.

Sponsors

Centre Jean Perrin
Lead SponsorOTHER
Association Nationale des Patients atteints de cancers de l'oeil (A.N.P.A.C.O.)
CollaboratorUNKNOWN

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient with a personal history of uveal melanoma (newly diagnosed, under treatment or in follow-up) * Enrolled in or benefiting from a social security scheme

Exclusion criteria

* Causal pathogenic variation identified in BAP1 or MBD4 * Patient does not consent to constitutional genetic analysis for diagnostic purposes * Patient not consenting to a constitutional genetic analysis for research purposes * Pregnant and breast-feeding women * Patients under guardianship or trusteeship

Design outcomes

Primary

MeasureTime frameDescription
Identify new candidate genes for hereditary cancer predisposition in patients with uveal melanoma by constitutional exome analysisAt baselineVariants of interest are selected from the data using the following filter: * Variant with frequency \< 1% (GnomAD) * Shared by at least 2 sufferers in the cohort * Truncating (nonsense, with frame shift, on a canonical splice site -2, -1 and +1 +2) * Missense from a list of "cancer" genes and Combined Annotation Dependent Depletion (CADD) score \> 20 (COSMIC Tier1 and Tier2) Variants will be interpreted using various databases and prediction tools: * Functions: genecards, pubmed, uniprot * Expression profiles: cbioportal, GEPIA * For splice variants: CADD, Splice AI * For exonic variants: CADD, SIFT, Polyphene

Secondary

MeasureTime frameDescription
Explore genes known to be involved in other cancer predisposition already described in the occurrence of uveal melanoma, but whose association has not yet been established with certainty.At baselineNumber of patients with a mutation on BRCA1, BRCA2, CHEK2, PALB2, POT1, MSH6 or MLH1

Countries

France

Contacts

CONTACTAngeline GINZAC COUVÉ
angeline.ginzac@clermont.unicancer.fr0473278005
PRINCIPAL_INVESTIGATORMathis LEPAGE, Dr

Centre Jean Perrin

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 20, 2026